Figure 2.

Schematic of experimental design and hypothesis. ∗Treatment patients are patients with atrial fibrillation (AF) + elevated CHA₂DS₂-VASc score (≥2 for men or ≥3 for women) + not on anticoagulation (AC) before the first appointment with a treatment provider in 2019 for the pre-launch era OR the first appointment with a treatment provider in 2020 for the post-launch era. ∗∗Control patients are patients with AF + elevated CHA₂DS₂-VASc score (≥2 for men or ≥3 for women) + not on AC before the appointment with a control provider in 2019 for the pre-launch era OR the first appointment with a control provider in 2020 for post-launch era. These patients did not see a treatment provider in the pre- or post-launch era, respectively. †Treatment providers comprise cardiology providers and primary care providers at study sites (including physicians, nurse practitioners, and physician assistants). ††Control providers comprise all other providers (including physicians, nurse practitioners, and physician assistants). CHA₂DS₂-VASc = stroke risk score consisting of congestive heart failure, hypertension, age 75+, diabetes, stroke, vascular disease, age 65 to 75, sex.